Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan + amoxicillin dual therapy for Helicobacter pylori eradication
ChiCTR2400092511Phase 4Recruiting
- Sponsor
- Eighth Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of keverprazan in Helicobacter pylori infection (9 arms), sponsored by Eighth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Helicobacter pylori eradication rate. Started Nov 2024; status: recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2400092511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092511.